Navigation Links
Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
Date:6/11/2009

SAN FRANCISCO, June 11 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada), a clinical-stage biopharmaceutical company, announced today that a $10 million grant from the Ontario Institute for Cancer Research (OICR) has been received by the Centre for Cancer Therapeutics at Ottawa Hospital Research Institute (OHRI). A large portion of this grant will fund research and development in the lab of Dr. John Bell, Jennerex's chief collaborator for the discovery and development of oncolytic viral therapeutics for cancer patients. Funding will support the translation of discoveries into medical products with the potential to prolong the lives of cancer patients. The grant, which provides $10 million (CAD) over four years, will fund the research and development of novel therapeutics including the development of Jennerex's oncolytic viral therapy products. Jennerex products have shown tumor destruction and safety in Phase 1 and 2 clinical trials.

"We are very pleased that Dr. Bell and Jennerex's oncolytic virus technologies have been given this vote of confidence by the Ontario Institute for Cancer Research. This funding will bolster the translation of Dr. Bell's promising research into important cancer therapeutics," stated David H. Kirn, M.D., president and chief executive officer of Jennerex. "We believe that there is significant potential in Ontario for medical innovation and development, and we value our partnerships in Ontario a great deal."

"This collaboration has been a great example of academia and industry working together to translate biological research into cutting edge therapies quickly and effectively," said Dr. John Bell, Senior Scientist at the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa.

Jennerex is conducting Phase 2 clinical trials for several types of cancer in Ontario, Canada. In addition, the company has a strong and collaborative relationship with world class investigators at OHRI. Jennerex oncolytic virus products are being manufactured in the "Mulcahy Manufacturing Unit" at OHRI, Ontario's first GMP facility dedicated to oncolytic virus production. Some of these development costs will be covered by the OICR grant. Some of the translational research funding will help support R&D, including human trials on Jennerex clinical candidates JX-594 and JX-929.

About the Ontario Institute for Cancer Research (OICR)

The OICR is dedicated to research in prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation.

About the Ottawa Hospital Research Institute

The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the University's Faculties of Medicine and Health Sciences. The OHRI includes more than 1,300 scientists, clinical investigators, graduate students, postdoctoral fellows, and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. www.ohri.ca

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Hospital Research Institute/University of Ottawa. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
Breaking Medicine Technology:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... Atlanta, GA (PRWEB) , ... April 25, 2017 , ... ... to their neck and back pain with a reputable physician in their area, announces ... The CRM protects patient information for patients who are looking for reputable physicians to ...
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
(Date:4/24/2017)... ... 24, 2017 , ... Michael Vick announced his retirement earlier this year from ... overall number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made ... the most career rushing yards by a quarterback (6,109) and the most rushing yards ...
(Date:4/24/2017)... ... , ... The bar for just about everything—apparel, eyewear, cars and even phone ... pop and film stardom.(1) Not to be left out is that most desired of ... the gamut from being encrusted with jewels and precious metals to, at the very ...
Breaking Medicine News(10 mins):